Login
Chemomab Therapeutics Ltd logo

Chemomab Therapeutics Ltd

chemomab.com

Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company employs 12 full-time employees The company went IPO on 2012-08-14. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$7.553M
Current Assets
2026 Q2
$9.957M
Current Liabilities
2026 Q2
$1.553M
Current Ratio
2026 Q2
641.15%
Total Assets
2026 Q2
$10.24M
Total Liabilities
2026 Q2
$1.553M
Book Value
2026 Q2
8.685M
Cash
2026 Q2
$5.999M
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $20.505 Million

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support